Kristian Schønning
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kristian Schønning has a total of 398 co-authors. Here are the top co-authors by number of shared publications:
- Martin Schou Pedersen
Department of Clinical Microbiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
7 shared publications - Jens Bukh
Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
5 shared publications Katrine Hartung Hansen
Department of Clinical Microbiology, Copenhagen University Hospital—Amager and Hvidovre , Copenhagen , Denmark
4 shared publications- Marie Helleberg
Department of Infectious Diseases, Rigshospitalet , Copenhagen
4 shared publications - Michael Perch
Department of Clinical Medicine University of Copenhagen Copenhagen Denmark
4 shared publications - Gabriele Bianco
Department of Experimental Medicine, University of Salento, Lecce, Italy
3 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Elsevier in SSRN Electronic Journal
Rapid PCR Panel Testing for Pulmonary Exacerbations in Cystic Fibrosis and Primary Ciliary Dyskinesia: A Diagnostic Evaluation
Background: Culture‐based methods may delay antibiotic therapy during pulmonary exacerbations (pEX) in people with cystic fibrosis (CF) and primary ciliary dyskinesia (PCD). Rapid polymerase chain reaction panel testing (PPT) may help bridge this diagnostic gap. Hence, this study evaluated the role of PPT in pEX diagnostics in CF/PCD by comparing pathogen detection, laboratory turnaround time, and the use of antibiotic therapy. Methods: In this diagnostic evaluation pilot study, sputum samples from adults with CF/PCD presenting with pEX symptoms were analyzed using both PPT (BioFire® FilmArray® Pneumonia Panel) and conven-tional culture-based methods between November 2023 and April 2024. Results: Eighty-three unique pEX episodes were included. Pathogenic bacteria were detected in 63% of PPT and 64% of the cultures, with concordant bacterial findings in 54% of samples. Agreement was substantial for Pseudomonas aeruginosa (κ=0.62) and Staphylococcus aureus (κ=0.80), but lower for Haemophilus influenzae and Moraxella catarrhalis. Viruses were detected by PPT in 36% of samples. Median turnaround time was 1.0 day for PPT versus 4.1 days for the culture-based method. Empiric antibiotic therapy was initiated in 31 pEXs and only 4 (13%) were modified based on PPT. In the 52 pEXs not empirically treated, antibiotics were initiated in 22 (42%) of the pEXs after PPT and 25 (48%) of the pEXs remained untreated. No change in antibiotic therapy was made based on culture results. Conclusion: Despite concordance in only half of sputum samples, PPT may still contribute to more in-formed antibiotic prescribing in people with CF/PCD not receiving empiric therapy during pEXs.
- 23 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessRapid PCR Panel Testing for Pulmonary Exacerbations in Cystic Fibrosis and Primary Ciliary Dyskinesia: A Diagnostic Evaluation
Background: Culture‐based methods may delay antibiotic therapy during pulmonary exacerbations (pEX) in people with cystic fibrosis (CF) and primary ciliary dyskinesia (PCD). Rapid polymerase chain reaction panel testing (PPT) may help bridge this diagnostic gap. Hence, this study evaluated the role of PPT in pEX diagnostics in CF/PCD by comparing pathogen detection, laboratory turnaround time, and the use of antibiotic therapy. Methods: In this diagnostic evaluation pilot study, sputum samples from adults with CF/PCD presenting with pEX symptoms were analyzed using both PPT (BioFire® FilmArray® Pneumonia Panel) and conven-tional culture-based methods between November 2023 and April 2024. Results: Eighty-three unique pEX episodes were included. Pathogenic bacteria were detected in 63% of PPT and 64% of the cultures, with concordant bacterial findings in 54% of samples. Agreement was substantial for Pseudomonas aeruginosa (κ=0.62) and Staphylococcus aureus (κ=0.80), but lower for Haemophilus influenzae and Moraxella catarrhalis. Viruses were detected by PPT in 36% of samples. Median turnaround time was 1.0 day for PPT versus 4.1 days for the culture-based method. Empiric antibiotic therapy was initiated in 31 pEXs and only 4 (13%) were modified based on PPT. In the 52 pEXs not empirically treated, antibiotics were initiated in 22 (42%) of the pEXs after PPT and 25 (48%) of the pEXs remained untreated. No change in antibiotic therapy was made based on culture results. Conclusion: Despite concordance in only half of sputum samples, PPT may still contribute to more in-formed antibiotic prescribing in people with CF/PCD not receiving empiric therapy during pEXs.
- Open Access
- 9 October 2026
- Published by Wiley in Transplant Infectious Disease
Prophylaxis Durations and Risks of Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients: An International, Multicenter Cohort Study
Background: The optimal duration of cytomegalovirus (CMV) prophylaxis in solid organ transplant recipients (SOTr) remains undetermined. We evaluated real‐life preventive strategies on the incidence of CMV disease in an international SOTr cohort. Methods: All CMV IgG donor (D)+/recipient (R)− or R+ SOTr in Zürich, Lausanne, and Copenhagen (2008–2022) were followed 12‐month post‐transplantation. Multivariable Poisson regression examined associations between antiviral prophylaxis duration and risk of CMV infection and CMV disease at time of infection diagnosis. Results: We included 3203 non‐lung (2057 kidney, 815 liver, 331 heart) and 620 lung transplant recipients. Strategies for CMV prophylaxis durations varied from none to ≥ 12 months. For D+/R− non‐lung SOTr, no prophylaxis with preemptive therapy only versus 3 months of prophylaxis was associated with higher risk of CMV infection and disease (adjusted incidence rate ratio [aIRR] [95% CI] 2.46 [1.69–3.57], and 2.82 [1.18–6.68]). Risk did not differ between 3 and 6 months of prophylaxis. For D+/R− lung transplant recipients, 3 versus 6 months of prophylaxis was associated with higher risk of CMV infection and high CMV DNAemia (2.74 [1.36–5.52] and 8.10 [1.89–41.90]), but not significantly higher risk of CMV disease. Irrespective of antiviral prophylaxis duration, incidence of CMV disease was lower among R+ compared to D+/R− SOTr. Conclusions: In a setting with CMV surveillance after prophylaxis, 3 months of antiviral prophylaxis seems adequate to prevent CMV disease in D+/R− non‐lung SOTr, whereas lung transplant recipients may benefit from longer duration of prophylaxis. Risk of CMV disease was low among R+ SOTr, irrespective of antiviral prophylaxis.
- 9 October 2026
- Published by Wiley in Transplant Infectious Disease
Open AccessProphylaxis Durations and Risks of Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients: An International, Multicenter Cohort Study
Background: The optimal duration of cytomegalovirus (CMV) prophylaxis in solid organ transplant recipients (SOTr) remains undetermined. We evaluated real‐life preventive strategies on the incidence of CMV disease in an international SOTr cohort. Methods: All CMV IgG donor (D)+/recipient (R)− or R+ SOTr in Zürich, Lausanne, and Copenhagen (2008–2022) were followed 12‐month post‐transplantation. Multivariable Poisson regression examined associations between antiviral prophylaxis duration and risk of CMV infection and CMV disease at time of infection diagnosis. Results: We included 3203 non‐lung (2057 kidney, 815 liver, 331 heart) and 620 lung transplant recipients. Strategies for CMV prophylaxis durations varied from none to ≥ 12 months. For D+/R− non‐lung SOTr, no prophylaxis with preemptive therapy only versus 3 months of prophylaxis was associated with higher risk of CMV infection and disease (adjusted incidence rate ratio [aIRR] [95% CI] 2.46 [1.69–3.57], and 2.82 [1.18–6.68]). Risk did not differ between 3 and 6 months of prophylaxis. For D+/R− lung transplant recipients, 3 versus 6 months of prophylaxis was associated with higher risk of CMV infection and high CMV DNAemia (2.74 [1.36–5.52] and 8.10 [1.89–41.90]), but not significantly higher risk of CMV disease. Irrespective of antiviral prophylaxis duration, incidence of CMV disease was lower among R+ compared to D+/R− SOTr. Conclusions: In a setting with CMV surveillance after prophylaxis, 3 months of antiviral prophylaxis seems adequate to prevent CMV disease in D+/R− non‐lung SOTr, whereas lung transplant recipients may benefit from longer duration of prophylaxis. Risk of CMV disease was low among R+ SOTr, irrespective of antiviral prophylaxis.
- Open Access
- 31 August 2026
- Published by Danish Medical Association in Ugeskrift for Læger
- p. 1-3
Carbapenemaseproducerende enterobakterier er kommet for at blive
- 31 August 2026
- Published by Danish Medical Association in Ugeskrift for Læger
- p. 1-3
Open AccessCarbapenemaseproducerende enterobakterier er kommet for at blive
- 4 August 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
Nonfermenting Gram-Negative Bacilli Other Than Pseudomonas and Acinetobacter Species in Pediatric Blood Cultures: A Multicenter European Analysis
Background: Nonfermenting Gram-negative bacilli other than Pseudomonas and Acinetobacter species are increasingly recognized as opportunistic pathogens in pediatric populations, yet their epidemiology and antimicrobial resistance remain poorly defined. Methods: We conducted a multicenter retrospective analysis across 56 hospital centers in 25 European countries, including pediatric blood culture isolates collected between January 2020 and December 2024. Species distribution and antimicrobial susceptibility profiles according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) current guidelines were analyzed. Results: A total of 382 isolates were included, spanning 19 genera and 40 species. Stenotrophomonas maltophilia was the most frequently identified species (46.9%; n = 179), followed by Roseomonas mucosa (10%; n = 38) and Sphingomonas paucimobilis (7.6%; n = 29). Susceptibility profiles were heterogeneous, with notable resistance across several species. For S. maltophilia , resistance to trimethoprim/sulfamethoxazole exceeded 10% (EUCAST), while full in vitro susceptibility to aztreonam/avibactam was observed. Preserved activity of carbapenems but high resistance to ceftazidime (EUCAST/CLSI), piperacillin/tazobactam (EUCAST/CLSI) and ciprofloxacin (CLSI) was observed for S. paucimobilis . Achromobacter several species showed concerning resistance patterns to carbapenems, piperacillin/tazobactam and trimethoprim/sulfamethoxazole (CLSI). Conclusions: Nonfermenting Gram-negative bacilli other than Pseudomonas and Acinetobacter species were frequently associated with healthcare exposure and complex resistance profiles. Their management is challenged by a lack of evidence and standardized susceptibility criteria. To optimize management, enhanced surveillance, improved diagnostic standardization and further clinical studies on emerging therapies are needed.
- 4 August 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
Nonfermenting Gram-Negative Bacilli Other Than Pseudomonas and Acinetobacter Species in Pediatric Blood Cultures: A Multicenter European Analysis
Background: Nonfermenting Gram-negative bacilli other than Pseudomonas and Acinetobacter species are increasingly recognized as opportunistic pathogens in pediatric populations, yet their epidemiology and antimicrobial resistance remain poorly defined. Methods: We conducted a multicenter retrospective analysis across 56 hospital centers in 25 European countries, including pediatric blood culture isolates collected between January 2020 and December 2024. Species distribution and antimicrobial susceptibility profiles according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) current guidelines were analyzed. Results: A total of 382 isolates were included, spanning 19 genera and 40 species. Stenotrophomonas maltophilia was the most frequently identified species (46.9%; n = 179), followed by Roseomonas mucosa (10%; n = 38) and Sphingomonas paucimobilis (7.6%; n = 29). Susceptibility profiles were heterogeneous, with notable resistance across several species. For S. maltophilia , resistance to trimethoprim/sulfamethoxazole exceeded 10% (EUCAST), while full in vitro susceptibility to aztreonam/avibactam was observed. Preserved activity of carbapenems but high resistance to ceftazidime (EUCAST/CLSI), piperacillin/tazobactam (EUCAST/CLSI) and ciprofloxacin (CLSI) was observed for S. paucimobilis . Achromobacter several species showed concerning resistance patterns to carbapenems, piperacillin/tazobactam and trimethoprim/sulfamethoxazole (CLSI). Conclusions: Nonfermenting Gram-negative bacilli other than Pseudomonas and Acinetobacter species were frequently associated with healthcare exposure and complex resistance profiles. Their management is challenged by a lack of evidence and standardized susceptibility criteria. To optimize management, enhanced surveillance, improved diagnostic standardization and further clinical studies on emerging therapies are needed.
- Open Access
- 22 May 2026
- Published by Elsevier in The Lancet Microbe
- Vol. 7 (7) , 101354
Gene transfer from NDM-5-producing and OXA-48-producing Enterobacter hormaechei ST79 on contaminated dicloxacillin capsules to other Enterobacterales in Europe, 2020–23: a retrospective, observational, molecular epidemiological study
- 22 May 2026
- Published by Elsevier in The Lancet Microbe
- Vol. 7 (7) , 101354
Open AccessGene transfer from NDM-5-producing and OXA-48-producing Enterobacter hormaechei ST79 on contaminated dicloxacillin capsules to other Enterobacterales in Europe, 2020–23: a retrospective, observational, molecular epidemiological study
- 6 March 2026
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (6) , 107772
Minor non-fermenting Gram-negative bacilli in Europe, 2020–2024 (MINOFEu)
- 6 March 2026
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (6) , 107772
Minor non-fermenting Gram-negative bacilli in Europe, 2020–2024 (MINOFEu)
- 3 February 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (6) , 1482-1490
Frequency of viral monitoring to detect cytomegalovirus infection and prevent disease in solid organ transplant recipients: An international, multicenter cohort study
- 3 February 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (6) , 1482-1490
Frequency of viral monitoring to detect cytomegalovirus infection and prevent disease in solid organ transplant recipients: An international, multicenter cohort study
- Open Access
- 26 January 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Genomic characterization and sub-clustering of Escherichia coli clonal complex 38 reveal host associated genetic markers
Background Escherichia coli clonal complex 38 (CC38) is a genetically diverse lineage increasingly linked to antimicrobial resistance and extraintestinal infections in humans. Despite its clinical and epidemiological relevance, its population structure, zoonotic potential, and ecological associations remain poorly understood. Methods We analyzed 242 human E. coli CC38 bloodstream isolates collected through Danish national surveillance, 83 isolates from food and production animals, and 2313 international genomes to investigate host associations and transmission dynamics. Phylogenetic reconstruction, Bayesian host prediction based on mobile genetic elements, and statistical testing of plasmid–host associations were used to delineate population structure and identify potential host-associated markers. Results Here we show that Danish CC38 isolates belong to multiple sub-lineages, with no evidence of foodborne outbreaks and limited hospital transmission. Bayesian host prediction supports a poultry origin for several distinct human sub-lineages. Global analyses of 2638 genomes reveal two major clusters: a poultry-associated Cluster I and a predominantly human-associated Cluster II, which subdivides into eight sub-lineages with distinct host, resistance, and virulence profiles. Two small plasmids, ColRNAI and Col(MG828), are strongly enriched in poultry and livestock isolates but largely absent from human-associated sub-clusters, indicating their value as host-associated genetic markers. Conclusions Our findings refine the phylogenetic structure of E. coli CC38 and identify plasmid markers that may enhance genomic surveillance of zoonotic transmission. These results highlight the importance of a One Health approach to monitor antimicrobial resistance across human, food, and animal reservoirs. Together, these insights support data-driven One Health surveillance and intervention strategies.
- 26 January 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Open AccessGenomic characterization and sub-clustering of Escherichia coli clonal complex 38 reveal host associated genetic markers
Background Escherichia coli clonal complex 38 (CC38) is a genetically diverse lineage increasingly linked to antimicrobial resistance and extraintestinal infections in humans. Despite its clinical and epidemiological relevance, its population structure, zoonotic potential, and ecological associations remain poorly understood. Methods We analyzed 242 human E. coli CC38 bloodstream isolates collected through Danish national surveillance, 83 isolates from food and production animals, and 2313 international genomes to investigate host associations and transmission dynamics. Phylogenetic reconstruction, Bayesian host prediction based on mobile genetic elements, and statistical testing of plasmid–host associations were used to delineate population structure and identify potential host-associated markers. Results Here we show that Danish CC38 isolates belong to multiple sub-lineages, with no evidence of foodborne outbreaks and limited hospital transmission. Bayesian host prediction supports a poultry origin for several distinct human sub-lineages. Global analyses of 2638 genomes reveal two major clusters: a poultry-associated Cluster I and a predominantly human-associated Cluster II, which subdivides into eight sub-lineages with distinct host, resistance, and virulence profiles. Two small plasmids, ColRNAI and Col(MG828), are strongly enriched in poultry and livestock isolates but largely absent from human-associated sub-clusters, indicating their value as host-associated genetic markers. Conclusions Our findings refine the phylogenetic structure of E. coli CC38 and identify plasmid markers that may enhance genomic surveillance of zoonotic transmission. These results highlight the importance of a One Health approach to monitor antimicrobial resistance across human, food, and animal reservoirs. Together, these insights support data-driven One Health surveillance and intervention strategies.
- Open Access
- 26 November 2025
- Published by Taylor & Francis in European Clinical Respiratory Journal
- Vol. 12 (1)
Cytomegalovirus and Crohn’s disease as competing causes of small bowel inflammation after double-lung transplantation
Cytomegalovirus (CMV) infection remains a significant cause of morbidity following solid organ transplantation, most frequently affecting the gastrointestinal tract. In transplant recipients presenting with diarrhea, alternative etiologies such as inflammatory bowel disease (IBD) should be considered. The emergence of antiviral resistance poses a therapeutic challenge, and molecular testing for resistance-associated mutations is essential in cases of treatment failure. A lung transplant recipient developed chronic diarrhea leading to functional intestinal failure. CMV infection was identified in intestinal biopsies and initially managed with two courses of valganciclovir. Due to persistent symptoms, genotypic analysis was performed, revealing UL97 mutations conferring ganciclovir resistance. Sequential therapy with foscarnet, maribavir, and letermovir achieved virological clearance, but diarrhea persisted. Small bowel enteroscopy with biopsies showed ongoing mucosal inflammation and minimal residual CMV activity. These findings were consistent with ganciclovir-resistant CMV enteritis coexisting with de novo Crohn’s disease. The patient was commenced on standard biological therapy for Crohn’s disease, resulting in marked clinical improvement and recovery. This case illustrates the diagnostic challenge of distinguishing CMV enteritis from de novo Crohn’s disease and determining the primary driver of the clinical presentation.
- 26 November 2025
- Published by Taylor & Francis in European Clinical Respiratory Journal
- Vol. 12 (1)
Open AccessCytomegalovirus and Crohn’s disease as competing causes of small bowel inflammation after double-lung transplantation
Cytomegalovirus (CMV) infection remains a significant cause of morbidity following solid organ transplantation, most frequently affecting the gastrointestinal tract. In transplant recipients presenting with diarrhea, alternative etiologies such as inflammatory bowel disease (IBD) should be considered. The emergence of antiviral resistance poses a therapeutic challenge, and molecular testing for resistance-associated mutations is essential in cases of treatment failure. A lung transplant recipient developed chronic diarrhea leading to functional intestinal failure. CMV infection was identified in intestinal biopsies and initially managed with two courses of valganciclovir. Due to persistent symptoms, genotypic analysis was performed, revealing UL97 mutations conferring ganciclovir resistance. Sequential therapy with foscarnet, maribavir, and letermovir achieved virological clearance, but diarrhea persisted. Small bowel enteroscopy with biopsies showed ongoing mucosal inflammation and minimal residual CMV activity. These findings were consistent with ganciclovir-resistant CMV enteritis coexisting with de novo Crohn’s disease. The patient was commenced on standard biological therapy for Crohn’s disease, resulting in marked clinical improvement and recovery. This case illustrates the diagnostic challenge of distinguishing CMV enteritis from de novo Crohn’s disease and determining the primary driver of the clinical presentation.
- Open Access
- 12 October 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (10) , 2342
Shiga Toxin-Producing E. coli (STEC) from Danish Patients, 1997–2023: Diagnostic Trends and Bacteriological Findings
Implementation of molecular detection methodology of Shiga toxin-producing Escherichia coli (STEC) in Danish patients began in 1997. Since then, changes in molecular detection methods and diagnostic criteria have led to the present situation, in which almost all diarrhoeal stool specimens are examined for STEC. Whole genome sequencing (WGS) of STEC isolates referred to the national reference laboratory has increased the detailed characterisation, and revealed a large spectrum, of STEC types, including cross-over pathotypes typically associated with extraintestinal disease or traveller’s diarrhoea. Association of subtype stx2a (and stx2d) with the risk of developing haemolytic uraemic syndrome (HUS) was confirmed. These changes have resulted in an increase in the number of diagnosed STEC cases from 31 cases in 1997 to 1432 in 2023. Similar increases in Europe have also been recorded. Culture of STEC is, on the other hand, declining, which poses a challenge to the identification of multiple STEC infections and outbreaks. Syndromic (PCR) test panels have also resulted in an increase in the detection of multiple microorganisms. Double or triple infections have increased the role of clinical microbiologists in interpreting and assessing the significance of diagnostic results and have also increased the need for high-quality curation of surveillance data.
- 12 October 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (10) , 2342
Open AccessShiga Toxin-Producing E. coli (STEC) from Danish Patients, 1997–2023: Diagnostic Trends and Bacteriological Findings
Implementation of molecular detection methodology of Shiga toxin-producing Escherichia coli (STEC) in Danish patients began in 1997. Since then, changes in molecular detection methods and diagnostic criteria have led to the present situation, in which almost all diarrhoeal stool specimens are examined for STEC. Whole genome sequencing (WGS) of STEC isolates referred to the national reference laboratory has increased the detailed characterisation, and revealed a large spectrum, of STEC types, including cross-over pathotypes typically associated with extraintestinal disease or traveller’s diarrhoea. Association of subtype stx2a (and stx2d) with the risk of developing haemolytic uraemic syndrome (HUS) was confirmed. These changes have resulted in an increase in the number of diagnosed STEC cases from 31 cases in 1997 to 1432 in 2023. Similar increases in Europe have also been recorded. Culture of STEC is, on the other hand, declining, which poses a challenge to the identification of multiple STEC infections and outbreaks. Syndromic (PCR) test panels have also resulted in an increase in the detection of multiple microorganisms. Double or triple infections have increased the role of clinical microbiologists in interpreting and assessing the significance of diagnostic results and have also increased the need for high-quality curation of surveillance data.